GSK strikes £370m deal with Chinese rival Jiangsu Hengrui to develop up to a dozen new medicines
The deal with Jiangsu Hengrui Pharmaceuticals comes as GSK focuses on growing its pipeline to negate declining revenues from top drugs and vaccines amid slowing demand and rising competition.
Under the deal, GSK will gain an exclusive licence to Hengrui's HRS-9821, which is being studied as a treatment for chronic obstructive pulmonary disease.
GSK shares rose 0.4 per cent, or 5.5p, to 1398p.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
7 minutes ago
- Reuters
Japan's real wage falls for sixth straight month in June
TOKYO, Aug 6 (Reuters) - Japan's real wages fell in June for the sixth consecutive month as inflation continued to outpace pay growth, government data showed on Wednesday, raising concerns about consumption-led recovery in the world's fourth-largest economy. Inflation-adjusted real wages, a key determinant of households' purchasing power, fell 1.3% in June from a year earlier, following a revised 2.6% drop in May. While June's drop in real wages was the slowest since January, it highlights broader pressures on consumption. Core inflation has exceeded the Bank of Japan's (BOJ) target, potentially giving the central bank leeway to raise interest rates as it unwinds years of loose monetary policy, but factors such as geopolitics and tariffs are looming economic risks. The consumer inflation rate the ministry uses to calculate real wages, which includes fresh food prices but not rent costs, rose 3.8% year-on-year in June, the lowest in seven months. Although special payments grew by 3% in June from the previous year due to summertime bonuses, they failed to keep up with a rise in inflation, a labour ministry official said. Total cash earnings, or nominal pay, increased 2.5% to 511,210 yen ($3,476) in June, picking up pace from a revised 1.4% rise in May and the fastest rise in four months. Regular pay, or base salary, rose 2.1% in June, while overtime pay edged up 0.9%. Major Japanese firms on average agreed to pay hikes of more than 5% during annual spring wage talks. The labour ministry had said previously the result may not be significantly reflected in the wage statistics until summer. Smaller firms, which lack labour unions, are slower to implement pay hikes compared with larger corporations. Wage trends, crucial to sustaining the momentum in consumption, are among key factors the BOJ is monitoring to determine the timing of the next rate hike. The BOJ last week kept its short-term interest rate steady at 0.50%, and said Japan will see rising wages and prices push underlying inflation towards the central bank's 2% target. At the same time, the central bank downgraded its assessment of consumption for the first time since March last year, and warned it would stagnate for the time being, squeezed by higher prices. A labour ministry panel on Monday proposed a 6% increase in the national average minimum wage for this fiscal year, the biggest such jump since at least 2002. ($1 = 147.0800 yen)
Reuters
3 hours ago
- Reuters
Rivian's loss bigger than expected as rare earth curbs raise costs, credits fade
Aug 5 (Reuters) - Rivian Automotive (RIVN.O), opens new tab reported a higher-than-expected quarterly loss on Tuesday as disruption in supply of rare earth metals used to make parts of its electric vehicles raised costs and income from credits sold to traditional automakers dwindled. Shares of the automaker fell nearly 5% in trading after the bell. China's curbs on the export of heavy rare earth metals —essential components for motors — sharply increased material costs and disrupted supply chains, driving up the cost of EV production in the U.S. Rivian's cost of revenue for each vehicle produced rose about 8% to $118,375 per unit sold from a year earlier, according to Reuters calculations. "That's really reflecting a much lower production volume, which was largely driven because of challenges we had within our supply base as a result of a lot of the changes in policy," CEO RJ Scaringe told Reuters. "Therefore, our costs look higher, but it's not as if our bill of materials grew or as if we became operationally less efficient." Rivian will shut down production for three weeks in September, after a one-week pause in the second quarter, to integrate key components and prepare for the launch of the R2 SUV next year. The company reported an adjusted loss per share of 80 cents for the second quarter, compared with analysts' average estimate of 65 cents, according to data compiled by LSEG. Rivian also flagged a bigger adjusted core loss this year, expecting it to be between $2 billion and $2.25 billion, compared with $1.7 billion to $1.9 billion previously forecast. The company largely blamed a tapering in the value of U.S. regulatory credits for the higher loss estimate. The elimination of penalties for automakers not meeting fuel economy standards by President Donald Trump's administration has drastically reduced demand for regulatory credits, which companies like Rivian previously sold to traditional automakers to help them avoid emissions fines. Meanwhile, Lucid (LCID.O), opens new tab cut its annual production forecast and missed Wall Street estimates for quarterly revenue as trade tensions took a toll on demand. The luxury EV maker's shares slid more than 7% in extended trading after the company also said it had issues with the supply of magnets, but had resolved it by using substitutes. The $7,500 federal EV tax credit expires at the end of September, eliminating a key competitive advantage that has driven demand, but analysts anticipate a surge in third-quarter sales as customers rush to make purchases before losing access to the incentive. Rivian said on Tuesday it expected record deliveries in the third quarter across its consumer and commercial segments. The Amazon-backed company's revenue for the second quarter stood at $1.3 billion, surpassing analysts' average estimate of $1.28 billion, according to data compiled by LSEG. Rivian delivered 10,661 vehicles in the second quarter, marking a 22% decline from the same period a year earlier, as the company limited production to prepare for its 2026 model year launch.
The Independent
3 hours ago
- The Independent
‘We will work collaboratively': Big Pharma admits it is discussing Trump's plan to lower drug prices
Pfizer CEO Albert Bourla says that his company and other large pharmaceutical firms are looking at working with the Trump administration to make more of their medicines available at lower costs to consumers. In a conference call with investors on Tuesday to discuss second-quarter earnings, Bourla said, 'We have serious discussions in the industry,' according to BioPharma Dive. 'I'm connected very often individually with all the major companies, and they are all ready to roll up their sleeves and execute something like that,' he added. Bourla leads Pfizer and is the board chair of PhRMA, the industry lobbying group. Pfizer and its partner Bristol Myers Squibb recently revealed plans to make their blood thinner Eliquis available at a lower price online. The firm previously started a direct-to-consumer service that lets patients book telehealth appointments, schedule vaccinations, and fill some prescriptions. 'We think it is a fantastic way to go ahead, so we will work collaboratively to do it,' said Bourla. Eli Lilly and Novo Nordisk, both makers of obesity drugs, have also put forward more ways that patients who pay in cash can access the weight-loss drugs directly. Other companies are also showing interest in the effort, looking at ways to make drugs available without pharmacy benefit managers — the middlemen getting rebates from drugmakers that insurers claim lower the overall cost, but not in ways that are clear to a patient filling a prescription. In letters to 17 drugmakers last week, Trump demanded that direct-to-consumer options be expanded. He said he would use 'every tool' available to him if the companies don't act to lower the cost of their products to prices seen in other industrialized countries. Trump has indicated that the policy would be limited to Medicaid, and analysts aren't unified on how much of an impact it would have. During the call on Tuesday, Bourla noted that he's in 'active discussions' with the 'highest levels of the U.S. government,' according to BioPharma Dive. That includes speaking to Trump, Health and Human Services Secretary Robert F. Kennedy Jr., and the Administrator of the Centers for Medicare and Medicaid Services, Mehmet Oz. 'The letter asks a lot from us,' said Bourla. 'But we are engaged in productive discussion with them and in general, I'm happy with the way that they listen to us.' Amid an investigation into pharmaceutical imports, the Commerce Department is expected to impose sector-specific tariffs. Trump told CNBC on Tuesday that his administration would at first put in place smaller tariffs on pharmaceuticals, which could subsequently rise to as much as 250 percent. While the tariffs would be expensive for drugmakers, analysts think that a phase-in period would mean that many companies could change their supply chains to avoid the worst of the financial repercussions, BioPharma Dive noted. Most of the biggest drugmakers have already revealed significant investment in manufacturing in the U.S. Pfizer indicated that it would be able to take on the tariffs this year, including any possible changes to its pricing, and still meet its financial forecast of revenues measuring between $61 billion and $64 billion. Trump has made impossible promises on drug prices, saying he's cut them by up to 1,500 percent. 'You know, we've cut drug prices by 1,200, 1,300, 1,400, 1,500 percent. I don't mean 50 percent, I mean 14 — 1,500 percent,' Trump told reporters on Sunday. This is inaccurate, as cutting prices by more than 100 percent would mean that consumers are being paid to take the drugs. The director of health policy at the University of Southern California's Schaeffer Center, Geoffrey Joyce, called the claim 'total fiction.' Mariana Socal is an associate professor of health policy and management at Johns Hopkins University. 'I find it really difficult to translate those numbers into some actual estimates that patients would see at the pharmacy counter,' she said. 'It's an objective fact that Americans are paying exponentially more for the same exact drugs as people in other developed countries pay, and it's an objective fact that no other Administration has done more to rectify this unfair burden for the American people,' a White House spokesperson said.
